Unmet needs in developing nanoparticles for precision medicine.
暂无分享,去创建一个
[1] P. Aguiar,et al. The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis. , 2016, Immunotherapy.
[2] Kwangmeyung Kim,et al. Early diagnosis of arthritis in mice with collagen-induced arthritis, using a fluorogenic matrix metalloproteinase 3-specific polymeric probe. , 2011, Arthritis and rheumatism.
[3] I. Kwon,et al. Theranostic nanoparticles for future personalized medicine. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[4] N. Jamieson,et al. nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial , 2015 .
[5] D Tripathy,et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] N. Svrzikapa,et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. , 2013, Cancer discovery.
[7] E. Van Cutsem,et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.
[8] Grace Hu,et al. Molecular MR imaging of melanoma angiogenesis with ανβ3‐targeted paramagnetic nanoparticles , 2005, Magnetic resonance in medicine.
[9] N. Hadipour,et al. Understanding the nanoparticle-protein corona complexes using computational and experimental methods. , 2016, The international journal of biochemistry & cell biology.
[10] S. Lai,et al. Anti-PEG immunity: emergence, characteristics, and unaddressed questions. , 2015, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.
[11] A. Salvati,et al. Balancing the effect of corona on therapeutic efficacy and macrophage uptake of lipid nanocapsules. , 2015, Biomaterials.
[12] D. Arango,et al. Fluorescent CSC models evidence that targeted nanomedicines improve treatment sensitivity of breast and colon cancer stem cells. , 2015, Nanomedicine : nanotechnology, biology, and medicine.
[13] F. Atyabi,et al. MUC1 aptamer conjugated to chitosan nanoparticles, an efficient targeted carrier designed for anticancer SN38 delivery. , 2014, International journal of pharmaceutics.
[14] W. Mark Saltzman,et al. A holistic approach to targeting disease with polymeric nanoparticles , 2015, Nature Reviews Drug Discovery.
[15] R. Valkema,et al. Tumor imaging and therapy using radiolabeled somatostatin analogues. , 2009, Accounts of chemical research.
[16] M. Mahmoudi,et al. Bypassing Protein Corona Issue on Active Targeting: Zwitterionic Coatings Dictate Specific Interactions of Targeting Moieties and Cell Receptors. , 2016, ACS applied materials & interfaces.
[17] A. J. Tavares,et al. Analysis of nanoparticle delivery to tumours , 2016 .
[18] A. Schneeweiss,et al. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. , 2016, The Lancet. Oncology.